← Bayer AG NA overview

Bayer AG NA vs Merck KGaA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bayer AG NA (BAYN.XETRA)

Q3 2026
▲3▼1

Bayer cuts legal risk, boosts cash, advances drugs; tariffs loom

  • Roundup settlement upheld, mRNA patent suits advance A US appeals court upheld Bayer's $7.25bn Roundup settlement, reducing legal uncertainty. Bayer also pushed patent lawsuits against Pfizer, BioNTech and Moderna over mRNA technology, potentially opening new revenue streams.

    This is the main legal development that reduced risk and supported the stock.

  • €3bn contraceptives stake sale to Apollo Bayer sold a €3bn stake in its contraceptives business to Apollo, strengthening its cash position. The deal helps fund pipeline investments and reduces balance sheet pressure.

    This capital move improved financial flexibility, a key driver for the quarter.

  • FDA approvals and pipeline progress The FDA approved sevabertinib, expanded Kerendia's use, and granted Priority Review to Lynkuet. Bayer also partnered with Kairos Pharma and Neste and announced a $2.2bn Ohio plant, advancing its drug pipeline and manufacturing footprint.

    These regulatory and pipeline wins support future revenue growth.

  • US tariffs and glyphosate opposition create headwinds New US pharmaceutical tariffs of 10–12.5% threaten Bayer's EU exports, while US farm groups oppose glyphosate duties on China. Valuation remains disputed, with bulls seeing 21% upside and bears 45% overvaluation amid lingering litigation provisions.

    These are the main risks that could pressure the stock despite positive developments.

August 2026
▲3▼1

Bayer wins legal and pipeline progress, but faces new US tariffs

  • US appeals court upholds $7.25bn Roundup settlement A US appeals court upheld Bayer's $7.25 billion Roundup settlement, reducing long-standing litigation risk. Final approval is still pending, but the decision removes a major cloud over the company.

    This is a major legal development that lowers uncertainty and supports the stock.

  • FDA approves sevabertinib and accepts Kerendia filing The FDA granted accelerated approval to sevabertinib for first-line HER2-mutant NSCLC and accepted Bayer's Kerendia filing for chronic kidney disease without diabetes. Both expand Bayer's market opportunities.

    These regulatory wins open new markets and support future revenue growth.

  • Pipeline and geographic expansion progress Bayer advanced Phase III cardiac imaging and Phase II atrial fibrillation programs, gained Canadian approvals, expanded distribution, and formed a biofuel partnership with Neste. These moves broaden its product reach and partnerships.

    Pipeline and geographic expansion show Bayer's efforts to grow beyond current products.

  • New US tariffs on pharmaceuticals threaten exports New US tariffs of 10–12.5% on pharmaceuticals threaten Bayer's EU exports, potentially raising costs and hurting US sales. The EU trade deal remains unratified, adding uncertainty.

    These tariffs could pressure Bayer's earnings and create a headwind for the stock.

Latest
▲2▼1

Bayer's legal wins and drug pipeline progress drive the stock

  • FDA accepts Kerendia filing for kidney disease without diabetes The FDA accepted Bayer's application to expand Kerendia to chronic kidney disease patients without diabetes. If approved, this opens a large new patient group for a drug already growing fast, supporting future sales and profit.

    This regulatory milestone expands a key drug's market, directly boosting Bayer's growth outlook.

  • Bayer expands Canadian distribution and relaunches Alka-Seltzer Cold Bayer widened its Canadian distribution deal with Mint to include Xarelto and women's health products, and will relaunch Alka-Seltzer Plus as Alka-Seltzer Cold with value pricing. Both moves aim to reach more customers and lift consumer health sales.

    These commercial actions broaden product reach and address pricing pressure, supporting revenue growth.

  • US tariffs threaten EU pharma exports New US tariffs of 10% to 12.5% on many trading partners target pharmaceuticals, and Bayer is a major EU drug exporter. The EU trade deal is not ratified, so higher tariffs could raise costs and hurt Bayer's US sales.

    This is a real counterweight: tariffs could pressure Bayer's largest market and offset positive pipeline news.

September 2026
▲4

Bayer advances pipeline, legal wins, and US investment

  • FDA expands Kerendia to type 1 diabetes kidney disease The FDA approved Kerendia for chronic kidney disease in type 1 diabetes, its third US approval. This opens a new patient group for a drug already growing fast, supporting future sales and profit, which helps lift the shares.

    New regulatory approval expands a key drug's market, directly supporting Bayer's growth outlook.

  • Monsanto mRNA patent lawsuits against Pfizer, BioNTech, Moderna proceed A judge rejected bids to dismiss Monsanto's patent suits over mRNA technology used in COVID-19 vaccines. This keeps alive a potential new revenue stream from licensing or damages, reducing legal uncertainty and supporting the stock.

    New legal development that could bring in money and shows Bayer's patents have value.

  • FDA grants Priority Review to Lynkuet for breast cancer hot flashes The FDA accepted Bayer's application and granted Priority Review for Lynkuet to treat hot flashes in breast cancer patients on endocrine therapy. If approved, it would be the first such treatment, opening a new market and boosting growth prospects.

    New regulatory milestone for a potential first-in-class treatment, adding to Bayer's pipeline value.

  • Bayer to invest $2.2 billion in new Ohio manufacturing site Bayer plans a $2.2 billion pharmaceutical plant in Ohio, creating 600 jobs and supporting its oncology, heart, and kidney drug portfolio. This shows commitment to its largest market and long-term growth, which investors view favorably.

    New major capital investment signals confidence in future growth and US expansion.

▲4

Bayer advances pipeline, legal wins, and US investment

  • FDA expands Kerendia to type 1 diabetes kidney disease The FDA approved Kerendia for chronic kidney disease in type 1 diabetes, its third US approval. This opens a new patient group for a drug already growing fast, supporting future sales and profit, which helps lift the shares.

    New regulatory approval expands a key drug's market, directly supporting Bayer's growth outlook.

  • Monsanto mRNA patent lawsuits against Pfizer, BioNTech, Moderna proceed A judge rejected bids to dismiss Monsanto's patent suits over mRNA technology used in COVID-19 vaccines. This keeps alive a potential new revenue stream from licensing or damages, reducing legal uncertainty and supporting the stock.

    New legal development that could bring in money and shows Bayer's patents have value.

  • FDA grants Priority Review to Lynkuet for breast cancer hot flashes The FDA accepted Bayer's application and granted Priority Review for Lynkuet to treat hot flashes in breast cancer patients on endocrine therapy. If approved, it would be the first such treatment, opening a new market and boosting growth prospects.

    New regulatory milestone for a potential first-in-class treatment, adding to Bayer's pipeline value.

  • Bayer to invest $2.2 billion in new Ohio manufacturing site Bayer plans a $2.2 billion pharmaceutical plant in Ohio, creating 600 jobs and supporting its oncology, heart, and kidney drug portfolio. This shows commitment to its largest market and long-term growth, which investors view favorably.

    New major capital investment signals confidence in future growth and US expansion.

▲4

Bayer advances drug pipeline and Roundup settlement, lifting sentiment

  • Roundup settlement clears court hurdle A US appeals court rejected a challenge to Bayer's $7.25 billion Roundup settlement, keeping the case on track for a September 14 review. This reduces the legal cloud that has weighed on the shares for years, though final approval is still pending.

    It is the biggest single overhang on Bayer's stock and the news directly reduces that uncertainty.

  • FDA approves sevabertinib for first-line lung cancer Bayer won FDA accelerated approval for sevabertinib in first-line HER2-mutant NSCLC, based on a 75% response rate. This expands the drug's use to newly diagnosed patients, opening a larger market and supporting future sales growth.

    A new approval for a key cancer drug directly adds a new revenue opportunity and validates Bayer's pipeline.

  • Pipeline progress in cardiac imaging and atrial fibrillation Bayer's Phase III REVEAL study for a cardiac amyloidosis imaging agent met its goals, and a Phase II trial began for a new atrial fibrillation drug. Both are early but show Bayer's research engine is producing candidates beyond its current products.

    These are new clinical milestones that strengthen the long-term pipeline story investors are watching.

  • Expanded Canadian approval and biofuel partnership Canada broadened approval of LYNKUET for breast-cancer-related hot flashes, adding a new patient group. Separately, Bayer partnered with Neste to scale winter canola for biofuels, creating a new market for its seeds and crop technology.

    Both are fresh commercial expansions that add incremental revenue streams in health and agriculture.

July 2026
▲3

Bayer cuts legal risk, raises cash, and expands pipeline

  • Bayer seeks US duties on Chinese glyphosate Bayer asked Washington to impose duties on Chinese-made glyphosate, saying it is sold at artificially low prices. If successful, this would reduce competition and protect Bayer's US glyphosate business, supporting future earnings. However, US farm groups oppose the move, warning of higher costs for farmers.

    This is a new regulatory push that could directly benefit Bayer's crop science earnings by limiting cheap imports.

  • Bayer sells €3bn minority stake in contraceptives unit to Apollo Bayer sold a non-controlling stake in its long-acting reversible contraceptives business to Apollo for €3 billion. This strengthens Bayer's capital structure and financial flexibility, helping it manage bond maturities and litigation costs. Bayer keeps full operational control of the unit.

    This new deal brings in significant cash, reducing balance sheet pressure and supporting the stock.

  • Bayer partners with Kairos Pharma on prostate cancer combination Bayer will evaluate its radiopharmaceutical XOFIGO with Kairos Pharma's ENV-105 in metastatic prostate cancer. The combination aims to overcome drug resistance and could expand XOFIGO's use in a market worth up to $1.3 billion. This supports Bayer's oncology pipeline.

    This new collaboration could boost Bayer's pharmaceutical growth prospects, a positive for long-term revenue.

  • Bayer stock rallies 83% but valuation debate continues Bayer shares have surged 83% over the past year, yet valuation screens still show a discount. Bulls see the stock as 21% undervalued, while bears argue it is 45% overvalued due to ongoing litigation risks and provisions. The debate centers on whether the market is correctly pricing these risks.

    This highlights the tug-of-war between Bayer's strong rally and lingering legal concerns, giving a balanced view of what drives the stock.

▲3

Bayer cuts legal risk, raises cash, and expands pipeline

  • Bayer seeks US duties on Chinese glyphosate Bayer asked Washington to impose duties on Chinese-made glyphosate, saying it is sold at artificially low prices. If successful, this would reduce competition and protect Bayer's US glyphosate business, supporting future earnings. However, US farm groups oppose the move, warning of higher costs for farmers.

    This is a new regulatory push that could directly benefit Bayer's crop science earnings by limiting cheap imports.

  • Bayer sells €3bn minority stake in contraceptives unit to Apollo Bayer sold a non-controlling stake in its long-acting reversible contraceptives business to Apollo for €3 billion. This strengthens Bayer's capital structure and financial flexibility, helping it manage bond maturities and litigation costs. Bayer keeps full operational control of the unit.

    This new deal brings in significant cash, reducing balance sheet pressure and supporting the stock.

  • Bayer partners with Kairos Pharma on prostate cancer combination Bayer will evaluate its radiopharmaceutical XOFIGO with Kairos Pharma's ENV-105 in metastatic prostate cancer. The combination aims to overcome drug resistance and could expand XOFIGO's use in a market worth up to $1.3 billion. This supports Bayer's oncology pipeline.

    This new collaboration could boost Bayer's pharmaceutical growth prospects, a positive for long-term revenue.

  • Bayer stock rallies 83% but valuation debate continues Bayer shares have surged 83% over the past year, yet valuation screens still show a discount. Bulls see the stock as 21% undervalued, while bears argue it is 45% overvalued due to ongoing litigation risks and provisions. The debate centers on whether the market is correctly pricing these risks.

    This highlights the tug-of-war between Bayer's strong rally and lingering legal concerns, giving a balanced view of what drives the stock.

Q2 2026
▲4

Supreme Court Roundup win reshapes Bayer's legal risk

  • Supreme Court ends failure-to-warn Roundup claims The US Supreme Court ruled 7-2 that federal pesticide law blocks state failure-to-warn claims, throwing out a $1.25 million verdict and barring similar future suits. This removes the biggest legal cloud over Bayer, cutting years of litigation costs and uncertainty, and sent the stock up about 17-20%.

    This is the single biggest new event and the main reason the stock moved sharply.

  • Roundup settlement still needs final court approval A legal challenge to Bayer's proposed $7.25 billion Roundup settlement stays in Missouri state court, with a final approval hearing on July 9. The Supreme Court win covers most claims, but this settlement is still a step Bayer must clear, so some legal uncertainty remains.

    It is the main counterweight to the Supreme Court win and tells readers the legal story is not fully closed.

  • Bayer buys Perfuse eye-disease drug Bayer completed its acquisition of Perfuse Therapeutics for $300 million upfront, up to $2.45 billion with milestones, gaining a Phase II eye implant for glaucoma and diabetic retinopathy. This adds a new late-stage asset to Bayer's pharmaceutical pipeline, supporting longer-term growth.

    It is a new pipeline-strengthening deal that affects Bayer's future earnings potential.

  • Bayer partners with Iambic on AI drug discovery Bayer will use Iambic Therapeutics' AI platform to find new small-molecule drugs for hard-to-treat targets, aiming to speed up early research. This could make Bayer's drug pipeline more productive over time, a positive for future revenue, though financial terms were not disclosed.

    It is a new technology collaboration that could improve Bayer's long-term drug discovery output.

June 2026
▲4

Supreme Court Roundup win reshapes Bayer's legal risk

  • Supreme Court ends failure-to-warn Roundup claims The US Supreme Court ruled 7-2 that federal pesticide law blocks state failure-to-warn claims, throwing out a $1.25 million verdict and barring similar future suits. This removes the biggest legal cloud over Bayer, cutting years of litigation costs and uncertainty, and sent the stock up about 17-20%.

    This is the single biggest new event and the main reason the stock moved sharply.

  • Roundup settlement still needs final court approval A legal challenge to Bayer's proposed $7.25 billion Roundup settlement stays in Missouri state court, with a final approval hearing on July 9. The Supreme Court win covers most claims, but this settlement is still a step Bayer must clear, so some legal uncertainty remains.

    It is the main counterweight to the Supreme Court win and tells readers the legal story is not fully closed.

  • Bayer buys Perfuse eye-disease drug Bayer completed its acquisition of Perfuse Therapeutics for $300 million upfront, up to $2.45 billion with milestones, gaining a Phase II eye implant for glaucoma and diabetic retinopathy. This adds a new late-stage asset to Bayer's pharmaceutical pipeline, supporting longer-term growth.

    It is a new pipeline-strengthening deal that affects Bayer's future earnings potential.

  • Bayer partners with Iambic on AI drug discovery Bayer will use Iambic Therapeutics' AI platform to find new small-molecule drugs for hard-to-treat targets, aiming to speed up early research. This could make Bayer's drug pipeline more productive over time, a positive for future revenue, though financial terms were not disclosed.

    It is a new technology collaboration that could improve Bayer's long-term drug discovery output.

▲4

Supreme Court Roundup win reshapes Bayer's legal risk

  • Supreme Court ends failure-to-warn Roundup claims The US Supreme Court ruled 7-2 that federal pesticide law blocks state failure-to-warn claims, throwing out a $1.25 million verdict and barring similar future suits. This removes the biggest legal cloud over Bayer, cutting years of litigation costs and uncertainty, and sent the stock up about 17-20%.

    This is the single biggest new event and the main reason the stock moved sharply.

  • Roundup settlement still needs final court approval A legal challenge to Bayer's proposed $7.25 billion Roundup settlement stays in Missouri state court, with a final approval hearing on July 9. The Supreme Court win covers most claims, but this settlement is still a step Bayer must clear, so some legal uncertainty remains.

    It is the main counterweight to the Supreme Court win and tells readers the legal story is not fully closed.

  • Bayer buys Perfuse eye-disease drug Bayer completed its acquisition of Perfuse Therapeutics for $300 million upfront, up to $2.45 billion with milestones, gaining a Phase II eye implant for glaucoma and diabetic retinopathy. This adds a new late-stage asset to Bayer's pharmaceutical pipeline, supporting longer-term growth.

    It is a new pipeline-strengthening deal that affects Bayer's future earnings potential.

  • Bayer partners with Iambic on AI drug discovery Bayer will use Iambic Therapeutics' AI platform to find new small-molecule drugs for hard-to-treat targets, aiming to speed up early research. This could make Bayer's drug pipeline more productive over time, a positive for future revenue, though financial terms were not disclosed.

    It is a new technology collaboration that could improve Bayer's long-term drug discovery output.

Merck KGaA (MRK.XETRA)

Q3 2026
▲2▼1

Merck KGaA advances Bio-Techne deal, raises guidance, but faces German rebate and Healthcare headwinds

  • Guidance raised on strong Q2 results Merck KGaA increased its 2026 outlook after Q2 organic sales grew 4.1% and EBITDA pre rose 9.3%, driven by Life Science and Electronics. This signaled confidence in continued momentum.

    The guidance raise reflects better-than-expected performance and is a new positive development this quarter.

  • Pipeline and regulatory wins The company achieved FDA Breakthrough status for lupus drug enpatoran, updated the European Erbitux label, made fertility acquisitions, and reported positive remigromig trial results. UBS also named Merck a favoured patent-light compounder.

    These pipeline and regulatory milestones are new positive catalysts that support future growth.

  • German rebate hike and Healthcare decline Germany's healthcare reform raised mandatory drug rebates, which Merck warned harms investment and innovation. Meanwhile, Healthcare fell 3.4% due to U.S. competition and Mavenclad's patent loss.

    This is a new negative factor that pressured the Healthcare segment and overall sentiment.

August 2026
▲4

Merck KGaA raises outlook, buys Bio-Techne, and posts drug wins

  • Raised 2026 guidance on Life Science and Electronics strength Merck lifted its full-year 2026 outlook after Q2 organic sales rose 4.1% and EBITDA pre climbed 9.3% to 1.6 billion euros. Life Science and Electronics (AI/data-center chips) led; Healthcare fell 3.4% on U.S. competition and Mavenclad patent loss. Higher profit expectations support the share price.

    Guidance raise is the core earnings driver behind the stock's re-rating this period.

  • Bio-Techne takeover clears key hurdles toward $11.3 billion deal Bio-Techne shareholders approved Merck's $73-a-share cash buyout, and the U.S. antitrust waiting period expired. The deal, worth about $11.3 billion including debt, is expected to close late 2026 or early 2027 with roughly 140 million euros of annual cost savings. It expands Merck's life-science tools business.

    The acquisition is a major capital move that reshapes Merck's Life Science portfolio and is now near closing.

  • Pipeline progress: fertility drugs acquired and eye-disease drug succeeds EMD Serono bought PostEra's two preclinical fertility programs, adding oral alternatives to IVF injections. Separately, remigromig met the main goal in the pivotal BRUNELLO trial for diabetic macular edema, though it showed more eye side effects than the control. Both strengthen the healthcare pipeline.

    New drug assets and a pivotal trial win are the main healthcare growth catalysts this period.

  • Electronics and screening markets expand, with new Japan investment Merck plans to invest over 70 million euros in an advanced semiconductor materials center in Japan, betting on chip demand. A separate report projects the high-throughput screening market to grow 10.7% a year to $45.9 billion by 2031, with Merck among key players. Both support its Electronics and Life Science units.

    These show structural demand growth in two of Merck's three core businesses.

Latest
▲4

Merck KGaA raises outlook, buys Bio-Techne, and posts drug wins

  • Raised 2026 guidance on Life Science and Electronics strength Merck lifted its full-year 2026 outlook after Q2 organic sales rose 4.1% and EBITDA pre climbed 9.3% to 1.6 billion euros. Life Science and Electronics (AI/data-center chips) led; Healthcare fell 3.4% on U.S. competition and Mavenclad patent loss. Higher profit expectations support the share price.

    Guidance raise is the core earnings driver behind the stock's re-rating this period.

  • Bio-Techne takeover clears key hurdles toward $11.3 billion deal Bio-Techne shareholders approved Merck's $73-a-share cash buyout, and the U.S. antitrust waiting period expired. The deal, worth about $11.3 billion including debt, is expected to close late 2026 or early 2027 with roughly 140 million euros of annual cost savings. It expands Merck's life-science tools business.

    The acquisition is a major capital move that reshapes Merck's Life Science portfolio and is now near closing.

  • Pipeline progress: fertility drugs acquired and eye-disease drug succeeds EMD Serono bought PostEra's two preclinical fertility programs, adding oral alternatives to IVF injections. Separately, remigromig met the main goal in the pivotal BRUNELLO trial for diabetic macular edema, though it showed more eye side effects than the control. Both strengthen the healthcare pipeline.

    New drug assets and a pivotal trial win are the main healthcare growth catalysts this period.

  • Electronics and screening markets expand, with new Japan investment Merck plans to invest over 70 million euros in an advanced semiconductor materials center in Japan, betting on chip demand. A separate report projects the high-throughput screening market to grow 10.7% a year to $45.9 billion by 2031, with Merck among key players. Both support its Electronics and Life Science units.

    These show structural demand growth in two of Merck's three core businesses.

July 2026
▲3▼1

Merck KGaA expands life-science and pipeline while German drug rebates bite

  • Bio-Techne acquisition at 36% premium Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, an $11.3 billion deal at a 36% premium. Buying a profitable life-science tools maker expands Merck's lab-supplies business and signals confidence, which supports the share price.

    This is the largest new deal and a direct driver of Merck KGaA's valuation.

  • UBS backs Merck KGaA as patent-light compounder UBS reiterated an overweight stance on European pharma and named Merck KGaA a favoured patent-light compounder, citing improving earnings and low valuations. More investor money flowing into the sector and into Merck specifically can lift the share price.

    Analyst positioning directly influences demand for the stock.

  • German healthcare reform raises pharma rebates Germany's Bundestag passed a reform cutting health costs by over €16 billion, raising mandatory rebates drugmakers pay. Merck KGaA warned this harms investment and innovation, a real headwind to future earnings and a counterweight to the positive news.

    This is the main negative force on Merck KGaA's home-market profitability.

  • Pipeline wins and AI partnership cut costs Merck KGaA's lupus drug enpatoran won FDA Breakthrough Therapy status, Erbitux got a European label update, and a multi-year AI deal with Evinova aims to speed trials and cut costs. These advances support future revenue and efficiency.

    Pipeline and technology progress are core to Merck KGaA's long-term growth story.

▲3▼1

Merck KGaA expands life-science and pipeline while German drug rebates bite

  • Bio-Techne acquisition at 36% premium Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, an $11.3 billion deal at a 36% premium. Buying a profitable life-science tools maker expands Merck's lab-supplies business and signals confidence, which supports the share price.

    This is the largest new deal and a direct driver of Merck KGaA's valuation.

  • UBS backs Merck KGaA as patent-light compounder UBS reiterated an overweight stance on European pharma and named Merck KGaA a favoured patent-light compounder, citing improving earnings and low valuations. More investor money flowing into the sector and into Merck specifically can lift the share price.

    Analyst positioning directly influences demand for the stock.

  • German healthcare reform raises pharma rebates Germany's Bundestag passed a reform cutting health costs by over €16 billion, raising mandatory rebates drugmakers pay. Merck KGaA warned this harms investment and innovation, a real headwind to future earnings and a counterweight to the positive news.

    This is the main negative force on Merck KGaA's home-market profitability.

  • Pipeline wins and AI partnership cut costs Merck KGaA's lupus drug enpatoran won FDA Breakthrough Therapy status, Erbitux got a European label update, and a multi-year AI deal with Evinova aims to speed trials and cut costs. These advances support future revenue and efficiency.

    Pipeline and technology progress are core to Merck KGaA's long-term growth story.

Q2 2026
▲3

Merck KGaA Buys Bio-Techne for $11.3B, Launches Gene Therapy Venture

  • Bio-Techne Acquisition Merck KGaA agreed to buy Bio-Techne for $11.3 billion, its largest deal since 2015. The $73 per share cash offer is a 36% premium. The deal is expected to immediately boost profitability with €140 million in annual cost savings. Shares jumped 5.3% on the news.

    This is the biggest new event driving the stock, directly boosting Merck's life sciences business and investor confidence.

  • Saturnus Bio Collaboration Merck KGaA invested $50 million upfront in Saturnus Bio, a biotech developing gene therapies for rare heart diseases. Merck gets exclusive rights to acquire Saturnus later. This adds a new technology platform and pipeline option in precision cardiology.

    This new partnership shows Merck's push into high-growth gene therapy, supporting future revenue potential.

  • Keytruda EU Approval Merck KGaA received European Commission approval for Keytruda combined with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. This expands the label for a key cancer drug, potentially increasing sales in Europe.

    A new regulatory approval for a major drug adds to Merck's oncology revenue stream.

June 2026
▲3

Merck KGaA Buys Bio-Techne for $11.3B, Launches Gene Therapy Venture

  • Bio-Techne Acquisition Merck KGaA agreed to buy Bio-Techne for $11.3 billion, its largest deal since 2015. The $73 per share cash offer is a 36% premium. The deal is expected to immediately boost profitability with €140 million in annual cost savings. Shares jumped 5.3% on the news.

    This is the biggest new event driving the stock, directly boosting Merck's life sciences business and investor confidence.

  • Saturnus Bio Collaboration Merck KGaA invested $50 million upfront in Saturnus Bio, a biotech developing gene therapies for rare heart diseases. Merck gets exclusive rights to acquire Saturnus later. This adds a new technology platform and pipeline option in precision cardiology.

    This new partnership shows Merck's push into high-growth gene therapy, supporting future revenue potential.

  • Keytruda EU Approval Merck KGaA received European Commission approval for Keytruda combined with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. This expands the label for a key cancer drug, potentially increasing sales in Europe.

    A new regulatory approval for a major drug adds to Merck's oncology revenue stream.

▲3

Merck KGaA Buys Bio-Techne for $11.3B, Launches Gene Therapy Venture

  • Bio-Techne Acquisition Merck KGaA agreed to buy Bio-Techne for $11.3 billion, its largest deal since 2015. The $73 per share cash offer is a 36% premium. The deal is expected to immediately boost profitability with €140 million in annual cost savings. Shares jumped 5.3% on the news.

    This is the biggest new event driving the stock, directly boosting Merck's life sciences business and investor confidence.

  • Saturnus Bio Collaboration Merck KGaA invested $50 million upfront in Saturnus Bio, a biotech developing gene therapies for rare heart diseases. Merck gets exclusive rights to acquire Saturnus later. This adds a new technology platform and pipeline option in precision cardiology.

    This new partnership shows Merck's push into high-growth gene therapy, supporting future revenue potential.

  • Keytruda EU Approval Merck KGaA received European Commission approval for Keytruda combined with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer. This expands the label for a key cancer drug, potentially increasing sales in Europe.

    A new regulatory approval for a major drug adds to Merck's oncology revenue stream.